Daily Top 50 Gainers & Losers

Market Regime — the colored bar under each day is the market's overall “weather,” scored from the indexes (trend, fear/VIX, small-cap breadth). It's market-wide context, not a stock pick: even a great company gets dragged down in a red tape. Read it to gauge when to lean in vs. wait for calmer water — click any day for the full read.

Risk-On · supportive Neutral Risk-Off · headwind Stress · fear

Market Recap · Thursday, August 6, 2026

Snapshot: Aug 6, 2026 · 6:00 PM 100 stocks analyzed

Strong Up Day

Thu, Aug 6, 2026 Tech Rally Extreme

Nasdaq and S&P 500 surge nearly 4.9% and 3.7% in a tech-led rally where extreme dispersion saw 50 gainers average +33% and 50 losers average -26%, with earnings-driven mega-move…

60% Tech and broad-market strength defined the day as NASDAQ Composite rocketed 4.88%, NASDAQ-100 climbed 4.51%, and S&P 500 surged 3.66%, with VIX falling 5.25% signaling calm beneath the volatility. Earnings season catalyzed names like DOCS (+72% on revenue beat), CELZ (+64% on patent allowance), HTZ (+42% on earnings surprise), IOVA (+40% on record revenue), and TEAM (+37.6% on guidance beat), reflecting broad-based repricing across growth stocks.
25% Extreme single-stock dispersion dominated with 50 gainers averaging +33% and 50 losers averaging -26%, marking a stock-picker's bonanza where Healthcare captured 31% of gainers while losing ground in the top losers. Debutants like KRO, PAYS, ATNI, HNST, and ALEC all returned to the top-50 gainers list with news-grounded catalysts, signaling fresh opportunities being unearthed by the market.
15% Downside pain remained acute despite the rally, with mega-losers like TDUP (-50.7% on weak guidance), UWMC (-35.1% on -428% earnings surprise), and TTD (-29.3% on revenue miss) highlighting the cost of disappointing earnings even on a strong tape. NXTT extended its four-day losing streak on the losers list, and persistent weakness in Software and select Healthcare names offset the day's upside celebration.

Healthcare drove 31% of gainers 5 names returned after long absences NXTT · 4-day losers streak KRO — first appearance PAYS — first appearance

Market Regime

Thu, Aug 6, 2026 Risk-On conf: medium macro · prototype

+46

Tailwind −100 … +100 · + tailwind / − headwind

VIX15.2 p3 Drawdown-0.3% Held4d · building SinceAug 3

Top drivers: VIX percentile ▲ S&P vs 20d avg ▲ S&P drawdown (60d) ▲

processId: history-market-regime

Market Indexes

Thu, Aug 6, 2026 13

S&P 500

7,709.96

+272.33

+3.66%

Dow Jones

53,885.10

+1,677.04

+3.21%

NASDAQ Composite

26,348.35

+1,226.17

+4.88%

NASDAQ 100

29,373.33

+1,266.98

+4.51%

DJ US Total Market

76,287.08

+2,603.46

+3.53%

Russell 1000

4,196.80

+145.31

+3.59%

S&P MidCap 400

3,834.39

+69.92

+1.86%

Russell 2000

3,001.55

+55.45

+1.88%

Russell 2500

1,282.88

−6.43

-0.50%

Russell 3000

4,380.92

+148.74

+3.51%

Nasdaq Financial-100

7,504.59

−52.37

-0.69%

NIFTY 50

24,636.00

+252.40

+1.04%

VIX

15.15

−0.84

-5.25%

Biggest Gainers

Thu, Aug 6, 2026 50

GAUZ

Gauzy Ltd. Ordinary SharesTechnology

$0.44+$0.23

+87.2%

NASDAQ · Mkt cap $6.9 M

No news headlines were found in the last 48 hours to explain Gauzy's 87% surge, suggesting the move may be driven by technical factors, short covering, or unindexed catalyst activity rather than disclosed company news.

Gauzy Ltd experienced a dramatic 87.19% single-day gain on August 6, 2026, yet zero news headlines appeared in the Yahoo Finance RSS feed during the preceding 48 hours. This disconnect between magnitude of move and absence of public disclosure is notable. For a micro-cap stock trading below $0.50, common drivers of such moves absent traditional news include short squeeze dynamics if the stock carries high short interest or borrow constraints, technical breakouts from sustained lows triggering momentum or algorithmic buying, or unindexed announcements made through other channels not yet syndicated to major news aggregators. Gauzy operates in smart glass and photochromic technology, sectors prone to speculative interest. Without confirmed catalyst, the true driver remains unknown, though the absence of earnings, regulatory, or M&A news from major sources suggests the move may reflect technical or sentiment-based activity rather than fundamental development.

DSY

Big Tree Cloud Holdings Limited Ordinary SharesConsumer Defensive

$3.38+$2.55

+76.1%

NASDAQ · Mkt cap $18 M

No news headlines were found in the last 48 hours, so the 76% gain on DSY cannot be attributed to a reported catalyst; the move likely reflects technical trading, delayed news pickup, or market speculation.

DSY experienced a dramatic 76% single-day surge while ranking as the second-biggest gainer on NASDAQ, yet no news stories appeared in the Yahoo Finance RSS feed over the prior 48 hours. This disconnect suggests either that a catalyst exists but has not yet been picked up by major financial news outlets, or that the move is driven by technical factors such as short covering, options expiration dynamics, retail sentiment, or other non-fundamental trading activity. Big Tree Cloud is a relatively small-cap Chinese cloud services company, a sector and geography that can be prone to volatile trading and delayed news dissemination. Without access to real-time corporate filings, earnings releases, or alternative data sources, it is impossible to confirm whether an actual business event occurred that day.

DOCS

Doximity, Inc.Healthcare

$20.63+$15.44

+72.3%

NYSE · Mkt cap $4.7 B

Doximity beat Q2 revenue expectations with $156.6 million in sales (up 7.3% year-over-year) and provided forward guidance, triggering a 72% single-day surge as the market repriced a previously undervalued stock.

The earnings beat on 2026-08-06 appears to be the primary catalyst. Doximity reported Q2 revenue exceeding consensus estimates with solid 7.3% year-over-year growth and offered Q3 guidance. This comes after research from 2026-08-05 suggested the stock was trading 41% below intrinsic value based on discounted cash flow analysis, meaning the market may have been significantly underpricing the company's fundamentals. The combination of a clean beat, forward guidance visibility, and valuation work published the day before highlighting undervaluation likely triggered institutional repositioning and short covering. A 72% move is extreme but plausible for a mid-cap healthcare software name that had suffered through a difficult prior year and was trading at depressed levels relative to cash flow generation.

CELZ

Creative Medical Technology Holdings, Inc.Healthcare

$1.16+$0.58

+63.9%

NASDAQ · Mkt cap $7.1 M

Creative Medical received a U.S. patent allowance for its exosome-based Type 1 diabetes immunotherapy, expanding IP protection for its cell-free MyeloCelz platform and multiple clinical programs, likely triggering the 64% single-day gain.

Both headlines released on 2026-08-06 announce the same patent allowance event: a Notice of Allowance for intellectual property covering Creative Medical's exosome-based approach to Type 1 diabetes treatment. The patent protects the cell-free MyeloCelz technology designed to suppress autoimmune destruction of insulin-producing cells and supports multiple programs including CELZ-101 and CELZ-201. For early-stage biotech companies with limited revenue, patent allowances that strengthen IP moats around clinical-stage programs are often viewed favorably by investors as they reduce risk of competitive encroachment and signal technical progress. The timing of two coordinated press releases amplified visibility. This is a classic catalyst for small-cap biotech: validated intellectual property in a meaningful therapeutic area.

WLDS

Wearable Devices LtdTechnology

$4.20+$1.66

+59.7%

NASDAQ · Mkt cap $6.0 M

No news headlines were found in the last 48 hours for WLDS, so the 59.71% gain cannot be directly attributed to a reported event; the move likely reflects technical trading, a delayed or off-platform announcement, or sector momentum in wearable devices.

The absence of any Yahoo Finance headlines in the past two days for a stock experiencing the fifth-largest single-day gain on NASDAQ is notable and unusual. Without reported earnings, product announcements, regulatory approvals, partnership news, or other catalyst events documented in the provided feed, the underlying cause remains unclear from publicly tracked sources. For a wearable devices company, typical catalysts would include new product launches, clinical trial results or regulatory clearance for health-monitoring features, partnership announcements with major tech firms, or upside earnings surprises. The magnitude of the move (nearly 60%) suggests a material event rather than normal volatility, but it may have occurred through channels not captured by the RSS feed, via social media or trading platforms, or could reflect short covering or technical breakout buying in a previously depressed name. Without additional information, we cannot distinguish between these scenarios.

SZZL

Sizzle Acquisition Corp.Financial Services

$10.39+$3.71

+55.5%

NASDAQ · Mkt cap $327 M

No news headlines were found in the last 48 hours, so the 55.54% jump cannot be attributed to a specific announced catalyst. The move likely reflects either a delayed market reaction to an earlier announcement, a rumor or social media event, or technical factors common to blank-check companies.

Sizzle Acquisition Corp. is a SPAC, a security type known for volatile price action driven by merger speculation, insider transactions, or redemption dynamics rather than fundamental operating news. The absence of any headlines in the Yahoo Finance RSS feed over the past 48 hours indicates that if a catalyst exists, it was either not covered by major news outlets, occurred before the 48-hour window, or is based on unverified market chatter. SPACs can experience sharp moves on rumors of merger targets, de-SPAC timing announcements, or technical factors such as options expiry or short covering. Without a confirmed news event, the jump falls into the category of speculative trading or delayed reaction to earlier information not captured in this snapshot.

ENSC

Ensysce Biosciences, Inc.Healthcare

$0.52+$0.18

+53.7%

NASDAQ · Mkt cap $7.5 M

Ensysce announced completion of the Cy Biopharma acquisition and secured up to $77 million in private financing on August 6th, adding an FDA Orphan Drug-designated pain therapy to its pipeline and extending its cash runway through Phase 2 development.

The headlines establish that Ensysce closed a meaningful corporate action on the date of the price surge: acquisition of Cy Biopharma, a clinical-stage neuroplastogenic therapy with FDA Orphan Drug Designation for Complex Regional Pain Syndrome, coupled with a $77 million private financing round. Orphan Drug status typically reduces regulatory hurdles and provides market exclusivity advantages, while the capital infusion addresses near-term dilution concerns for a cash-constrained biotech. For a micro-cap biotech stock trading at $0.52, a transformative M&A event combined with non-dilutive or modest-dilution financing can easily trigger a 50+ percent single-day rally. The timing of multiple news releases on the same date (announcements followed by completion confirmation) suggests a coordinated disclosure that likely caught broad retail and institutional attention.

HTZ

Hertz Global Holdings IncIndustrials

$2.01+$0.68

+42.2%

NASDAQ · Mkt cap $809 M

Hertz stock surged 42% on Thursday following Q2 2026 earnings that significantly beat Wall Street expectations, with a narrower-than-expected adjusted loss driven by record rental pricing and strong revenue growth despite a smaller fleet.

The headlines establish a clear earnings-driven catalyst. Hertz reported a Q2 2026 adjusted loss of $0.11 per share, which beat consensus estimates by 55 percent, while revenue of $2.40 billion exceeded expectations by 4.93 percent and grew 9.7 percent year-over-year. The company's strong pricing power and commercial execution stood out as key drivers, particularly notable given headwinds from vehicle recalls and a smaller fleet size. Multiple sources frame the results as offering relief to investors and supporting a turnaround narrative. The stock initially jumped 13-15.7 percent in premarket trading before closing up 42.24 percent, suggesting the full market reaction included additional short-covering or momentum. One article mentions ongoing index drops and litigation concerns, but the earnings beat appears to be the dominant near-term catalyst powering the move.

ZTG

Zenta Group Company LimitedIndustrials

$9.99+$2.84

+41.5%

NASDAQ · Mkt cap $30 M

No news headlines were found in the last 48 hours, so the 41% gain on August 6 lacks an identified catalyst. The jump may reflect a delayed market reaction, technical trading, or unreported company developments.

The absence of recent Yahoo Finance headlines means we cannot directly attribute ZTG's +41.46% move to earnings, guidance, regulatory action, or M&A. For a micro-cap or thinly traded stock like Zenta Group, such moves are sometimes driven by technical factors including short covering, retail accumulation, or delayed reactions to news not yet picked up by major outlets. Alternatively, the company may have issued a press release or announcement that has not yet propagated through the RSS feed used here. Without access to the company's investor relations page or real-time newswires, the specific catalyst remains opaque. The rank as the ninth biggest gainer suggests institutional or algorithmic participation, but that does not clarify whether the driver was fundamental or technical.

IOVA

Iovance Biotherapeutics IncHealthcare

$6.18+$1.77

+40.2%

NASDAQ · Mkt cap $3.9 B

Iovance surged 40% on record Q2 revenue of $99M (66% YoY growth) with Amtagvi cancer therapy sales at $91M, beating estimates and prompting upward guidance revision plus FDA Fast Track designation for a pipeline candidate.

The headlines establish a clear and multifaceted earnings beat. Iovance reported revenue of approximately $99M, representing 66% year-over-year growth and exceeding consensus estimates by 13.73%. More importantly, U.S. Amtagvi revenue alone reached $91M, demonstrating strong commercial traction for its tumor-infiltrating lymphocyte therapy. The company also achieved 56% gross margin, a significant improvement, and raised full-year guidance on this momentum. Additionally, the FDA granted Fast Track Designation for lifileucel in soft tissue sarcomas, which reduces regulatory friction for a late-stage program. Collectively, these developments signal both near-term commercial success and near-term clinical optionality, justifying a substantial one-day gain. The headlines also reference acquisition speculation, though no deal is announced.

AFJKR

Aimei Health Technology Co., Ltd Right

$0.14+$0.04

+40.0%

ASPN

Aspen Aerogels IncBasic Materials

$6.89+$1.89

+37.8%

NYSE · Mkt cap $452 M

Aspen Aerogels surged 37.84% after reporting Q2 earnings with a 17.84% revenue beat and raising Q3 guidance to $65-$80 million, driven by strong 81% quarter-over-quarter Thermal Barrier revenue growth.

The company reported Q2 results on August 6 that included a significant revenue surprise of 17.84% above estimates. More importantly, the earnings announcement highlighted a sharp acceleration in Thermal Barrier revenue, which grew 81% quarter-over-quarter to $29.5 million. Management also provided forward guidance for Q3 2026 revenue in the range of $65-$80 million with adjusted EBITDA of $7-$15 million, suggesting continued strong momentum. The combination of a beat on current results plus meaningful upward guidance and evidence of accelerating core business growth appears to have triggered substantial buying interest. While the company reported a net loss for the quarter, investors appear focused on the revenue trajectory, EBITDA potential, and the growth rate in the higher-margin Thermal Barrier segment, which serves the electrification and sustainability markets.

CPOP

Pop Culture Group Co., LtdCommunication Services

$0.36+$0.13

+37.6%

NASDAQ · Mkt cap $4.8 M

No news headlines were found in the last 48 hours, so the 37.61% gain is not directly attributable to a published announcement or earnings release. The move is likely driven by technical factors, retail trading interest, or unpublished company developments.

With zero news coverage in the Yahoo Finance RSS feed over the past two days, there is no headline-based explanation for CPOP's sharp 37.61% gain. Pop Culture Group is a small-cap stock trading at $0.36, which typically characterizes companies susceptible to several catalyst types not necessarily reflected in traditional financial news: possible short covering or momentum-driven retail buying, technical bounce off prior lows, rumors circulating on social media or message boards, insider buying signals, or a delayed market reaction to an older announcement. Without access to real-time trading volume, short interest data, or company filings from the snapshot date, we cannot distinguish between these possibilities. The absence of news combined with the dramatic percentage gain suggests either a non-public event or a technical/sentiment-driven revaluation.

TEAM

Atlassian Corp PLCTechnology

$110.28+$40.17

+37.6%

NASDAQ · Mkt cap $45 B

Atlassian reported Q2 2026 earnings that beat analyst expectations on both revenue and EPS, combined with optimistic forward guidance, driving a 37.6% stock surge.

The headlines establish a clear earnings catalyst. Atlassian reported adjusted EPS of $1.87 versus a consensus estimate of $1.50, a $0.37 or 24.7% beat. Revenue came in at $1.77 billion against expectations of $1.66 billion, representing a $0.11 billion beat and 27.6% year-over-year growth. Multiple sources note the company provided optimistic guidance for the subsequent quarter, though the specific forward revenue or earnings targets are not detailed in the excerpts provided. The magnitude of the move, ranking 14 among daily gainers, is proportional to this scale of earnings surprise combined with constructive forward commentary. The headlines reference strong cloud and AI capabilities as contributing factors to investor confidence, though these appear to be contextual color rather than a discrete new announcement.

VATE

Elev8 Brands, IncIndustrials

$7.40+$2.80

+37.0%

NYSE · Mkt cap $107 M

The provided news headline is about INNOVATE Corp., not VATE (Elev8 Brands), so no direct news catalyst can be identified for this 37% jump. The cause remains unclear from available evidence.

The only recent headline supplied refers to INNOVATE Corp.'s second-quarter results and mentions divisions like DBM Global and MediBeacon, which appear unrelated to Elev8 Brands. No news about VATE itself—no earnings, guidance, product launch, regulatory action, or corporate event—is present in the snapshot. A 37% single-day gain in a micro-cap or lower-liquidity stock can result from technical factors such as short covering, thin-float volatility spikes, options expiration mechanics, or social media attention, but these remain speculative without corroborating evidence. The timing and magnitude suggest either a catalyst not captured in this feed or market dynamics typical of lower-capitalization equities.

LTCH

Latch, Inc.Technology

$0.19+$0.05

+35.6%

NASDAQ · Mkt cap $31 M

No news headlines were found in the last 48 hours, so the 35.64% jump in LTCH cannot be attributed to a specific disclosed catalyst. The move likely reflects technical trading, short covering, or undisclosed market activity.

LTCH's sharp intraday gain of 35.64% occurred without any accompanying news in the Yahoo Finance RSS feed over the preceding two days. This creates a gap between price action and disclosed information. For a micro-cap stock trading at $0.19, typical catalysts that drive large single-day moves include short squeezes, technical breakouts above key resistance levels, options expiration mechanics, broader sector rotation, or acquisition rumors that may circulate on social media or alternative channels before reaching mainstream financial news feeds. Without access to earnings calendars, guidance updates, partnership announcements, or other company-specific events, the precise driver remains unknown. The absence of news does not rule out a real catalyst—it may simply mean the market moved ahead of formal disclosure or that the trigger originated outside tracked news sources.

INSM

Insmed IncHealthcare

$132.41+$33.38

+33.7%

NASDAQ · Mkt cap $28 B

Insmed surged 34% on strong Q2 earnings for its lung disease drug BRINSUPRI, which posted record revenue of $309.2 million with 49% sequential growth, prompting the company to raise full-year guidance and boost peak sales estimates to over $7 billion.

Insmed reported second-quarter 2026 results that significantly exceeded expectations, with the company delivering a +24.64% earnings surprise and +9.18% revenue surprise. The headline driver was BRINSUPRI, the company's lead lung disease therapeutic, which generated record quarterly revenue and demonstrated 49% sequential growth. Management responded to this commercial momentum by raising its 2026 full-year revenue guidance to $1.25 to $1.4 billion and substantially increasing its long-term peak sales expectations to over $7 billion. The company also noted continued steady growth from ARIKAYCE. The combination of a beat-and-raise earnings report with dramatic upward revision to peak sales multiples—a key valuation driver for biotech—typically catalyzes significant stock appreciation, particularly in a company with concentrated pipeline risk where one drug's success directly translates to expanded investor confidence in long-term value creation.

OPRT

Oportun Financial CorpFinancial Services

$8.05+$1.99

+32.8%

NASDAQ · Mkt cap $350 M

Oportun Financial reported strong Q2 2026 earnings with adjusted EPS up 35% year-over-year, beat guidance, and raised outlook, driving the +32.76% rally on fundamentals and analyst optimism.

Oportun delivered its seventh consecutive quarter of GAAP profitability with significant operational improvements. Adjusted EPS grew 35% year-over-year, GAAP net income rose 24% year-over-year, and adjusted EBITDA expanded 56% year-over-year. The company exceeded both earnings and revenue guidance, with earnings surprise of 27.27%. Credit metrics hit multi-year lows and interest expense declined. Management raised guidance following the outperformance. Additionally, Wall Street analysts issued a consensus price target implying 49.75% upside, suggesting analyst sentiment is constructive post-earnings. The combination of strong beat, multiple bottom-line and efficiency metrics showing improvement, and forward guidance raise created a clear catalyst for institutional and retail buyers on the morning of the release.

KRO

Kronos Worldwide IncBasic Materials

$8.21+$2.01

+32.4%

NYSE · Mkt cap $973 M

Kronos Worldwide surged 32.41% following a massive earnings beat on August 5th, delivering a 425% EPS surprise and 7.26% revenue beat for Q2 2026, which likely triggered institutional buying and short covering.

The headline evidence directly points to Kronos's second quarter earnings announcement on August 5th as the catalyst. The company reported net income of $15.2 million or $0.13 per share compared to a net loss of $9.2 million in the prior year quarter, representing a dramatic swing to profitability. The 425% earnings surprise is exceptionally large and would naturally attract significant attention from both value investors and short sellers covering positions. The positive revenue surprise of 7.26% further validates operational improvement. This is precisely the type of beat that can drive a stock from mid-pack obscurity into the top 20 gainers, particularly in titanium dioxide or specialty chemicals where earnings volatility and turnarounds are common. No countervailing negative news appears in the headlines to offset the earnings enthusiasm.

FIGS

FIGS, Inc.Consumer Cyclical

$11.25+$3.52

+32.1%

NYSE · Mkt cap $2.4 B

FIGS reported Q2 2026 earnings that beat revenue expectations with 28.8% year-over-year sales growth to $196.6 million and GAAP profit of $0.15 per share, driving a 32% stock surge on strong operational performance.

FIGS released second quarter 2026 financial results on August 6, 2026, that exceeded market expectations for revenue. The company reported sales of $196.6 million, representing 28.8% year-over-year growth, alongside positive earnings of $0.15 per share on a GAAP basis. An earlier earnings preview from August 5 had highlighted product innovation, global expansion, and demand momentum as key drivers, though tariffs and freight costs were noted as potential margin headwinds. The headline noting a 25.1% initial jump after earnings release, combined with the stock's final +32.06% close, indicates strong investor reception to both the top-line beat and bottom-line profitability. The magnitude of the move suggests the results materially exceeded consensus expectations and possibly included positive forward guidance or margin expansion commentary that reassured investors about operational execution despite cost pressures.

AZI

Autozi Internet Technology (Global) Ltd.Consumer Cyclical

$1.60+$0.39

+31.0%

NASDAQ · Mkt cap $3.5 M

No news headlines were published in the last 48 hours, so the 31% gain is unexplained by reported events; the move likely reflects technical trading, delayed news dissemination, or market rumors not yet captured in official feeds.

The absence of any recent news headlines is striking given the magnitude of the gain—a 31% single-day jump in a stock trading near $1.60 typically warrants explanation. For a micro-cap company like Autozi Internet Technology, such moves can be driven by several non-news-event categories: short covering or momentum buying in thinly traded securities, delayed announcement pickup across different news feeds, social media or retail-driven trading surges, technical breakouts above resistance levels, or sector rotation effects if competitors or related companies announced something relevant. Without headline confirmation, we cannot rule out speculative accumulation, rumor-driven trading, or simple technical rebound after prior weakness. The lack of news-feed coverage itself may indicate the catalyst remains localized to specific trading communities or has not yet hit mainstream financial media.

PAYS

Paysign IncTechnology

$12.40+$2.82

+29.4%

NASDAQ · Mkt cap $732 M

Paysign reported record Q2 2026 revenue up 48% with net income and adjusted EBITDA surging, while raising full-year guidance, driving the 29% stock rally on strong execution in its Patient Affordability and plasma segments.

The headlines establish that Paysign delivered a clean beat on topline and bottom-line metrics on August 5-6, 2026. Record quarterly revenue of $28.3 million representing 48% year-over-year growth, combined with a 113% increase in adjusted EBITDA, signal accelerating profitability. The company's decision to raise full-year guidance is a forward-looking positive catalyst that typically reassures investors about sustained momentum. The Patient Affordability business expansion and improving plasma utilization appear to be the primary growth drivers. This is textbook earnings-driven upside: strong execution, margin expansion, and management confidence. The 29% one-day move reflects a combination of relief that results met or exceeded expectations and enthusiasm for the raised outlook.

AEVA

Aeva Technologies, Inc.Technology

$25.21+$5.59

+28.5%

NASDAQ · Mkt cap $1.1 B

Aeva jumped 28.49% on announcement of a "transformational" hyperscaler deal and Q2 earnings beat, with service revenues nearly tripling and gross profit turning positive for the first time.

The stock's surge is grounded in two concrete developments released August 5–6. First, Aeva reported Q2 2026 results that beat earnings expectations by 6.82% while service revenues nearly tripled, pushing the company to positive gross profit despite a reported net loss. Second, and more significantly, the company announced launch of a new Optical Connectivity business segment and signed a major customer agreement with an unnamed hyperscaler, which Oppenheimer analysts characterized as "potentially transformational" with potential to drive billions in future revenue. The combination of demonstrated operational progress (revenue growth, margin improvement) plus entry into a large new market segment with an anchor customer appears to have convinced investors that the company has shifted from pre-revenue speculation to a credible growth story with near-term revenue visibility.

FEAM

5E Advanced Materials, Inc.Basic Materials

$1.74+$0.39

+28.4%

NASDAQ · Mkt cap $66 M

No news headlines were found in the last 48 hours for FEAM, so the 28.41% gain cannot be attributed to a specific announced catalyst. The move likely reflects technical trading, a delayed market reaction to older news, or unverified market rumors.

The absence of recent news headlines for a 28% single-day jump is notable and suggests the catalyst was not a major formal announcement picked up by Yahoo Finance RSS in the past two days. For a small-cap advanced materials company like 5E Advanced Materials, price swings of this magnitude can occur for several reasons: delayed market reaction to older earnings or guidance updates, short-covering by retail traders or squeezes, options-driven volatility on expiration dates, sector rotation into materials stocks, or unconfirmed social media activity or rumors. Without access to intraday trading volume, short interest levels, or options expiration data, pinpointing the mechanism is difficult. Advanced materials companies are often volatile and subject to momentum trading, especially at lower price points.

ATNI

ATN International IncConsumer Defensive

$30.64+$6.62

+27.6%

NASDAQ · Mkt cap $491 M

ATN International surged 27.56% following Q2 earnings that showed revenue growth and adjusted EBITDA expansion, plus a $268 million cash infusion from a partial sale of its U.S. tower portfolio and an expanded share repurchase program.

ATN International reported second-quarter 2026 results on August 5th that appear to have driven the rally. The company delivered 2% year-over-year revenue growth and 9% adjusted EBITDA growth, both of which beat or met market expectations. More significantly, the company received $268 million in cash from the initial closing of a U.S. tower portfolio sale, a material capital event that strengthens the balance sheet. Additionally, management increased the share repurchase authorization to $30 million and reaffirmed the 2026 outlook, signaling confidence in near-term prospects. While the earnings release notes an earnings surprise of negative 3516.67% (indicating a net loss versus expectations), the positive operational metrics, capital generation from the asset sale, and capital return program appear to have outweighed that metric in investor sentiment. The combination of organic growth, balance sheet improvement, and shareholder-friendly capital allocation likely drove the strong share price reaction.

SGHT

Sight Sciences, Inc.Healthcare

$7.11+$1.52

+27.2%

NASDAQ · Mkt cap $467 M

Sight Sciences posted stronger-than-expected Q2 earnings with 20% revenue growth, raised full-year guidance, secured FDA clearance for OMNI Ultra, and announced new insurance coverage, collectively driving the 27% gain on August 6.

The stock's sharp rise is grounded in multiple positive catalysts announced on August 5-6. The company reported a 46.67% earnings surprise and 7.55% revenue beat, with 20% year-over-year revenue growth driven by dry eye and interventional glaucoma segments. Management raised full-year 2026 revenue guidance and reduced adjusted operating expense guidance, signaling improving operational leverage. Additionally, Sight Sciences received FDA 510(k) clearance for the OMNI Ultra Surgical System for canaloplasty and announced Aetna coverage for OMNI and SION systems, both of which expand market access. While an analyst fair value estimate was cut from $9.35 to $8.40, this negative revision appears outweighed by the strength of the earnings beat, guidance raise, and regulatory/commercial wins. The combination of beat, raise, and FDA approval typically drives strong single-day moves in medical device stocks.

HNST

The Honest Company, Inc.Consumer Defensive

$5.42+$1.14

+26.9%

SITM

SiTime CorpTechnology

$687.58+$143.80

+26.4%

ALEC

Alector IncHealthcare

$1.87+$0.38

+25.2%

NASDAQ · Mkt cap $271 M

Alector reported Q2 2026 results and provided a business update on its ABC blood-brain barrier platform and lead Alzheimer's program AL137, likely driving the 25% intraday gain.

The headline confirms Alector released second quarter 2026 financial results and a business update on the same day as the price spike. The update specifically highlights progress on the company's ABC platform—a technology designed to deliver antibodies, enzymes, and siRNA across the blood-brain barrier—with AL137 positioned as the lead anti-amyloid beta antibody candidate for Alzheimer's disease. For a biotech company with a market cap implied by a $1.87 share price, positive clinical or operational updates on a flagship program typically elicit strong single-day gains. The headline does not provide specific financial metrics, clinical trial results, or regulatory milestones, so the exact driver within the update remains unclear from the text provided. However, the timing and context are consistent with a near-simultaneous catalyst and stock reaction.

MYO

Myomo IncHealthcare

$1.33+$0.27

+25.0%

NYSE · Mkt cap $74 M

Myomo reported Q2 2026 earnings on August 5-6 showing 21% revenue growth to $11.7M, a 72.1% gross margin, and both earnings and revenue beats, driving a 25% stock jump as the market rewarded strong operational progress and margin expansion.

Myomo delivered a strong quarterly performance that exceeded analyst expectations on both revenue and earnings metrics. The company reported revenue of $11.7 million, representing 21% year-over-year growth and beating estimates by 14.75%. More importantly, gross margin expanded to 72.1%, and the company nearly doubled its recurring patient revenue sources to 53% of total revenue, signaling improved business model durability and customer stickiness. The earnings surprise of 30% above expectations indicates the company achieved profitability or reduced losses more sharply than anticipated. For a small-cap medical device company like Myomo, demonstration of both revenue growth and margin expansion—particularly the shift toward recurring revenue—represents a meaningful inflection point that justifies strong investor enthusiasm on the day of disclosure.

TASK

TaskUs, Inc.Technology

$7.80+$1.51

+23.9%

NASDAQ · Mkt cap $725 M

TaskUs crushed Q2 earnings and revenue expectations on August 5-6, with revenue up 5% YoY to $308.9 million and a 13.79% EPS beat, driving the 23.91% gain as investors reward the outsourcing company's AI Services growth and beat on guidance.

TaskUs reported second-quarter 2026 results that exceeded Wall Street consensus on both top and bottom lines. Revenue came in at $308.9 million, representing 5% year-over-year growth and $10.9 million above the high end of prior guidance. The company delivered a 13.79% earnings surprise, indicating substantially stronger profitability than expected. Notably, growth in AI Services and Digital Customer Experience segments drove the outperformance. The stock's 23.91% one-day gain reflects the market's positive reaction to both the beat itself and the underlying business momentum in high-growth segments. This represents a classic post-earnings relief move combined with investor enthusiasm for the company's positioning in AI-driven services, which likely justifies a significant revaluation upward on the day.

PAYC

Paycom Software IncTechnology

$216.23+$41.41

+23.7%

NYSE · Mkt cap $10 B

Paycom delivered a strong Q2 earnings beat with 10% revenue growth, raised full-year 2026 guidance, and reported record margins and $1.4 billion in shareholder returns, directly catalyzing the 23.69% gain.

All nine news headlines from the past 48 hours converge on the same event: Paycom's Q2 2026 earnings announcement on August 5-6, 2026. The company beat earnings estimates by 21.93% and revenue estimates by 3.69%, with sales of $531.2 million (up 9.8% year-over-year). Management raised full-year 2026 revenue guidance to $2.20-$2.21 billion and highlighted record margins, automation-driven product expansion, and free cash flow above $650 million. The company also announced aggressive $1.4 billion in shareholder repurchases. These concrete operational and capital allocation achievements, combined with positive forward guidance, represent the type of comprehensive earnings beat that typically drives large single-day gains in software stocks. The consistency of positive commentary across multiple sources reinforces that this was a substantial market-moving catalyst.

DCTH

Delcath Systems, Inc.Healthcare

$15.48+$2.88

+22.9%

NASDAQ · Mkt cap $572 M

Delcath Systems reported Q2 earnings and revenue that beat analyst expectations, returned to profitability after recent losses, and achieved strong HEPZATO KIT sales growth, triggering the stock's best day in nearly 15 months with a 22.86% gain.

On August 6, 2026, Delcath announced Q2 2026 financial results showing revenue of $29.1 million, up 20% year-over-year, which exceeded consensus estimates by 15.88%. More significantly, the company posted an earnings surprise of 143.75%, returning to profitability after two consecutive quarters of losses. The earnings call highlights emphasized strong commercial expansion and growth in HEPZATO KIT sales, the company's flagship interventional oncology product for liver cancer treatment. The combination of a major earnings beat, profitable quarter, and accelerating product-driven revenue growth appears to have catalyzed substantial institutional and retail buying interest, pushing the stock to a fresh 52-week high and marking its strongest performance in approximately 15 months.

VAC

Marriott Vacations Worldwide CorpConsumer Cyclical

$124.85+$23.11

+22.7%

NYSE · Mkt cap $3.4 B

Marriott Vacations Worldwide (VAC) surged 22.71% on August 6 following the release of Q2 2026 earnings that beat both EPS and revenue estimates, with non-GAAP EPS up 15.4% and sales growth of 5.9% year-over-year.

The stock's strong rally is directly tied to better-than-expected financial results announced on earnings day. VAC delivered a 16.67% earnings surprise and a 3.39% revenue surprise relative to consensus estimates, with Q2 revenues reaching $1.32 billion and non-GAAP EPS of $2.31 per share. The company also demonstrated underlying business momentum with 5.9% year-over-year sales growth. Additionally, a leadership appointment of Vladimir Anokhin as Chief Strategy & Transformation Officer on August 4 may have signaled positive strategic direction ahead of the earnings release. The combination of a clear earnings beat and modest operational momentum in the vacation ownership segment appears sufficient to drive the substantial single-day gain.

PETZ

TDH Holdings IncReal Estate

$1.47+$0.27

+22.5%

NASDAQ · Mkt cap $12 M

No news headlines were available in the last 48 hours for PETZ, so the 22.5% gain likely reflects either technical trading, delayed market reaction to an earlier announcement, or a sector-wide move in pet retail stocks.

The absence of recent news headlines makes it impossible to identify a specific catalyst for today's 22.5% jump in PETZ. For a micro-cap stock trading at $1.47, large single-day moves can result from several common drivers: a delayed market reaction to earnings or guidance released outside the news window captured, short covering or technical breakout momentum (especially common in low-liquidity names), sector rotation into or out of pet retail, insider activity or M&A speculation, or simple volatility in thinly traded securities. Without access to earnings dates, analyst upgrades, SEC filings, or other corporate actions from the past week, we cannot pinpoint which mechanism drove this move. The stock's position as the 35th biggest gainer suggests material volume involvement rather than pure noise, but that alone does not identify the cause.

MATV

Mativ IncBasic Materials

$11.68+$2.09

+21.8%

NYSE · Mkt cap $691 M

Mativ announced Q2 2026 earnings that beat both EPS and revenue estimates, with an exceptional 78.57% earnings surprise, driving the stock up 21.79% on the day.

Mativ reported second quarter results on August 5, 2026, that substantially exceeded analyst expectations. The company delivered an earnings surprise of 78.57% and a revenue surprise of 4.58%, both beating consensus forecasts. A beat of that magnitude on the bottom line—nearly 79% above expectations—is a significant positive signal to the market and typically justifies a sharp single-day rally. The revenue beat, while more modest at 4.58%, is nonetheless positive and consistent with operational momentum. The stock's 21.79% gain reflects investor recognition that earnings quality and beat magnitude of this scale suggest either improved profitability, cost discipline, or better-than-anticipated business conditions. No forward guidance revision or other material news appears in the headlines, so the move is driven primarily by the reported results themselves.

GWAV

Greenwave Technology Solutions, Inc.Industrials

$4.28+$0.76

+21.6%

NASDAQ · Mkt cap $2.9 M

No news headlines were found in the last 48 hours, so the 21.59% jump in GWAV stock is unexplained by any disclosed catalyst. The move likely stems from technical trading, retail momentum, or undisclosed company developments.

A single-day gain of over 21 percent with zero corresponding news in the prior 48 hours is difficult to attribute to any specific catalyst. This pattern is common in smaller-cap stocks trading on lower volumes, where price moves can be driven by short covering, algorithmic trading, options-related hedging adjustments, or retail investor momentum rather than fundamental news. For a company like Greenwave Technology Solutions, which operates in industrial or technology sectors with typically lower visibility, the absence of news does not rule out internal developments that have not yet been announced publicly, but it means we cannot identify the specific trigger. Sector rotation, market-wide momentum, or delayed announcement dissemination through non-primary channels are also possibilities.

CACI

CACI International IncTechnology

$628.80+$111.08

+21.5%

NYSE · Mkt cap $14 B

CACI reported strong Q4 2026 earnings with 17.6% revenue growth, an earnings beat of 22.73%, and raised fiscal 2027 guidance targeting double-digit sales growth, prompting the 21.46% rally.

CACI International released fourth quarter and full-year 2026 results on August 5, 2026, that materially exceeded Wall Street expectations. The company reported 17.6% year-over-year revenue growth to $2.71 billion, with earnings per share and revenue each beating consensus estimates by 22.73% and 0.36% respectively. Management also issued fiscal 2027 guidance targeting double-digit sales growth with strong cash flow generation and highlighted record revenue and robust contract awards in the quarter. For a defense and intelligence contractor, this combination of beat, margin expansion, and forward guidance suggesting sustained momentum appears sufficient to drive the substantial single-day gain. The stock's ranking as the 38th biggest gainer on August 6 indicates broad participation in the move across the market.

CAI

CAI International IncHealthcare

$19.99+$3.53

+21.4%

NASDAQ · Mkt cap $7.2 B

Caris Life Sciences reported Q2 earnings on August 5-6 with 45% revenue growth, beat expectations, achieved break-even earnings, and raised full-year guidance, driving the 21.45% stock gain.

CAI reported second-quarter 2026 financial results that exceeded analyst expectations across multiple dimensions. Revenue grew 45% year-over-year, the company delivered a 100% earnings surprise by reaching break-even profitability in the quarter, and management raised full-year 2026 revenue guidance. The growth was driven by strong performance in molecular profiling services and strategic product launches, with record clinical volume reported. The combination of top-line growth, bottom-line profitability achievement, and upward guidance revision represents the classic catalyst for a significant single-day stock jump in a TechBio company. The earnings call highlights and press release were distributed on August 5 evening into August 6, aligning precisely with the trading date of the 21.45% gain. This is a textbook earnings-driven move based on beat-and-raise results.

ZONE

CleanCore Solutions IncIndustrials

$0.37+$0.06

+21.0%

EOLS

Evolus IncHealthcare

$7.41+$1.27

+20.6%

NASDAQ · Mkt cap $598 M

Evolus reported Q2 earnings on August 5-6 showing 21% revenue growth, break-even earnings (100% beat), raised full-year guidance, and achieved third consecutive quarter of positive adjusted EBITDA, driving a 20.6% single-day jump.

The stock surge is grounded in a strong earnings surprise and forward guidance raise announced on August 5-6. Evolus reported second-quarter revenue growth of 21% year-over-year, delivered a 100% earnings surprise by reaching break-even (versus expectations for a loss), and notably raised the lower end of its full-year 2026 revenue guidance. The company cited market-share gains in neurotoxins and hyaluronic acid injectable gels as drivers, plus strategic expansion into skin quality through a Profhilo partnership. A third consecutive quarter of positive adjusted EBITDA suggests the company has reached an inflection point toward sustained profitability. For a small-cap beauty/aesthetics company, this combination of growth acceleration, profitability achievement, and management confidence in raising guidance typically triggers significant single-day repricing, especially if prior expectations had been more muted.

CBAT

CBAK Energy Technology IncIndustrials

$0.60+$0.10

+20.0%

NASDAQ · Mkt cap $62 M

No news headlines were available in the last 48 hours to explain the 20% gain, so the catalyst remains unknown; the move could reflect technical trading, delayed news release, or sector momentum in battery technology stocks.

CBAK Energy Technology is a battery technology company, and a 20% single-day jump with zero supporting headlines in the prior 48 hours is atypical. This could indicate several non-mutually-exclusive scenarios: first, a material announcement (earnings, partnership, or product news) may have been released during market hours but has not yet propagated through Yahoo Finance's RSS feed at the time of this snapshot. Second, the stock may be responding to broader sector momentum if lithium-ion or energy storage stocks rallied as a group. Third, given the stock's low price point of $0.60, it may be subject to technical trading, short covering, or retail sentiment shifts that can drive outsized percentage moves on modest absolute volume. Without confirmed news, all of these remain hypotheses rather than established fact.

PEPG

PepGen Inc.Healthcare

$2.38+$0.40

+19.9%

NASDAQ · Mkt cap $201 M

PepGen announced positive clinical progress on its lead candidate PGN-EDODM1, advancing to the highest dose cohort in the Phase 2 FREEDOM2-DM1 study following Data Safety Monitoring Board review, coinciding with second quarter 2026 financial results.

On the morning of August 6, 2026, PepGen released two coordinated announcements: second quarter financial results and clinical advancement news for its primary pipeline asset PGN-EDODM1 in muscular dystrophy. The clinical milestone—approval to advance to the highest dose cohort following DSMB review—represents validation that prior dose levels were tolerated safely and that escalation is warranted. This is a concrete de-risking event for a clinical-stage biotech stock. Combined with the earnings release, the announcement likely triggered positive reassessment of both near-term trial trajectory and cash runway. Biotech stocks, particularly those in late preclinical or early clinical phases, often exhibit sharp gains on dose escalation approvals because they reduce technical and safety risk to future milestones. The 19.9% single-day move is typical for small-cap biotech responding to positive Phase 2 progression.

FIP

FTAI Infrastructure LLCIndustrials

$4.06+$0.67

+19.8%

NASDAQ · Mkt cap $480 M

FIP surged 19.79% following the release of Q2 2026 earnings that showed record adjusted EBITDA of $76.1 million (65% YoY growth) and progress on a $1.4 billion debt elimination plan, despite missing revenue estimates.

The earnings headlines establish that FIP reported a substantial beat on the metric that matters most to the market: adjusted EBITDA jumped from $45.9 million in Q2 2025 to $76.1 million, driven by strong performance in rail and terminal operations. The company also declared a $0.03 per share dividend and announced advancement of its Long Ridge asset sale and debt reduction strategy. Revenue did miss analyst expectations, but the market appears to have weighted the EBITDA beat and operational momentum more heavily than the top-line miss. The combination of record profitability, dividend declaration, and clear capital allocation strategy targeting deleveraging typically attracts value-oriented investors in the infrastructure sector. The 19.79% single-day move is consistent with a positive earnings surprise in a small-cap infrastructure stock.

PYXS

Pyxis Oncology, Inc.Healthcare

$3.75+$0.62

+19.7%

NASDAQ · Mkt cap $214 M

No news headlines were found in the last 48 hours, so the 19.74% gain likely stems from a clinical trial update, FDA decision, merger rumor, or other biotech catalyst not yet indexed by the RSS feed.

Pyxis Oncology is an early-stage oncology company, and a nearly 20% single-day jump with no recent headlines in the search results is atypical but not uncommon for small-cap biotech stocks. The gain could reflect a delayed market reaction to a press release issued outside the RSS window, an announcement made after market close yesterday that became widely known this morning, or coverage of a clinical development milestone. Alternatively, it may reflect short-covering, technical momentum in a thinly traded name, or an unconfirmed rumor in the biotech community. Without specific news content, we cannot definitively attribute the move to a concrete catalyst.

ALNT

Allient IncTechnology

$111.43+$18.37

+19.7%

NASDAQ · Mkt cap $1.5 B

Allient beat Q2 earnings and revenue estimates significantly while delivering double-digit revenue growth and record gross margin, triggering the 19.74% jump on strong execution across industrial automation, data center, and aerospace sectors.

Allient released Q2 fiscal 2026 results on August 5-6 that substantially exceeded analyst expectations. The company posted a 29.03% earnings surprise and 5.12% revenue surprise, with sales rising 10.2% year-over-year to $153.8 million. Non-GAAP earnings per share came in at $0.80, representing 30.6% outperformance versus consensus. The earnings call highlighted record gross margins and strong order momentum across multiple end markets including industrial automation, data center infrastructure, and aerospace and defense. Additionally, the company declared a quarterly cash dividend, signaling confidence in cash generation. The combination of significant earnings beat, margin expansion, double-digit growth, and robust demand signals across key verticals provides clear fundamental justification for the substantial single-day gain.

FNGR

FingerMotion, Inc.Communication Services

$0.34+$0.06

+19.5%

NASDAQ · Mkt cap $14 M

FingerMotion announced a leadership change on August 5th, bringing on a seasoned Nasdaq executive and corporate attorney as a new leader, likely triggering investor optimism about improved governance and strategic direction.

The headline confirms FingerMotion announced a leadership transition on August 5th, 2026, specifically highlighting the appointment of an executive with Nasdaq seniority and corporate law expertise. This type of announcement—particularly when emphasizing credentials like public company leadership experience—typically signals to the market that management quality and governance may improve. The timing aligns directly with the stock's 19.48% gain on August 6th. The announcement itself is incomplete in the provided excerpt, so we cannot assess whether additional strategic details were disclosed that might further explain the move. However, leadership changes at small-cap stocks frequently trigger positive reactions when the incoming executive has strong credentials, as investors interpret this as a potential inflection point for operational discipline and strategic execution.

INDI

indie Semiconductor, Inc.Technology

$3.44+$0.66

+19.4%

NASDAQ · Mkt cap $733 M

indie Semiconductor reported Q2 2026 results showing $64.0 million in revenue on August 6, triggering a 19.44% rally, likely driven by either a beat relative to consensus expectations or positive forward guidance not yet detailed in the available headline.

The company released its second quarter 2026 earnings after market close on August 6, 2026. The headline confirms Q2 revenue of $64.0 million but provides no context on profitability, margins, guidance, or how this compares to analyst estimates or prior-year results. A 19.44% same-day jump following earnings typically indicates either a significant revenue or earnings beat, improved guidance, or positive commentary on automotive semiconductor demand trends. Without the full earnings release details—including net income, gross margin, forward guidance, or management commentary—we cannot definitively attribute the move to a specific metric. However, given the stock's automotive semiconductor focus and current industry tailwinds, a positive surprise on revenue growth or margin expansion is a reasonable inference.

CJMB

Callan JMB Inc. Common StockIndustrials

$1.67+$0.25

+19.2%

NASDAQ · Mkt cap $15 M

Callan JMB announced formation of a new subsidiary, Callan Power, to manufacture transformers and electrical infrastructure domestically in Alabama, which likely triggered the 19% gain as investors responded positively to the new business venture.

The announcement of Callan Power as a wholly owned subsidiary represents a concrete strategic expansion into domestic manufacturing of critical electrical equipment, specifically transformers. This move signals both business diversification and positioning within the growing domestic infrastructure and electrical equipment market. The timing of the announcement on the day of the price jump and the stock's ranking as the 49th biggest gainer suggests the market viewed this favorably, likely seeing it as a value-accretive move or a response to infrastructure demand tailwinds. However, the headline provided is brief and does not include details on expected revenue, profitability timeline, capital requirements, or competitive advantages that might help assess the announcement's true impact on shareholder value.

ADIL

Adial Pharmaceuticals IncHealthcare

$4.88+$0.78

+19.0%

NASDAQ · Mkt cap $15 M

No relevant news headlines were found in the last 48 hours, so the 19% gain on August 6th likely reflects either a delayed market reaction to an unindexed announcement, a technical or sentiment-driven bounce, or institutional interest in the small-cap biotech name.

No news from Yahoo Finance RSS appears in the 48-hour window prior to this snapshot, which means any catalyst that drove the move either occurred earlier and is being priced in with a lag, was not captured by the RSS feed, or was non-news-based. Adial Pharmaceuticals is a small-cap biotech stock, a category that can experience sharp intraday moves on low volume from retail interest, short covering, or rumors not yet reflected in major news outlets. Without access to the actual news on August 6th itself or in the 48 hours prior beyond what was provided, attribution remains speculative. Possible categories include clinical trial results, a partnership announcement, insider activity, or purely technical/momentum-driven trading in a thinly traded name.

Biggest Losers

Thu, Aug 6, 2026 50

TDUP

ThredUp Inc.Consumer Cyclical

$3.09−$3.18

-50.7%

NASDAQ · Mkt cap $387 M

ThredUp reported Q2 earnings that met revenue expectations and showed strong growth metrics, but provided Q3 guidance below consensus, triggering a 50.7% stock collapse on profit-taking and disappointment over forward momentum.

ThredUp announced Q2 2026 results with record quarterly revenue of $90.8 million, up 17% year-over-year, alongside record active buyers at 1.77 million and double-digit order growth. These metrics beat or met consensus expectations. However, one headline explicitly states that Q3 revenue guidance of $88 million fell short of expectations, which represents a sequential decline from Q2. This guidance miss—signaling deceleration ahead—appears to have overwhelmed the positive beat on current-quarter results. The stock initially dropped 15.5% on August 5 after earnings, then fell an additional 35+ percentage points by August 6, suggesting either a second-day washout, short covering reversal, or negative analyst downgrades following the call. The broader industry tailwind mentioned (secondhand apparel market growing to $393 billion by 2030) did not offset investor concern over TDUP's near-term deceleration.

ATHHF

Aether Catalyst Solutions Inc.Consumer Cyclical

$0.00−$0.00

-36.5%

UWMC

UWM Holdings Corporation ClassFinancial Services

$1.19−$0.64

-35.1%

NYSE · Mkt cap $4.2 B

UWM Holdings swung to a Q2 adjusted loss and reported a massive negative earnings surprise of -428.57%, triggering a 35% stock collapse on the day of the earnings release.

On August 5-6, 2026, UWM Holdings reported second quarter 2026 results showing a swing to an adjusted loss, which stands in stark contrast to market expectations. The earnings surprise of -428.57% indicates the loss was far deeper than anticipated. While the company did beat revenue estimates by 1.88%, this minor positive was overwhelmed by the profitability miss. The stock fell more than 18% in premarket trading on August 6 and continued declining through the session to end down 35%. The company also announced a $2.05 billion strategic capital partnership with the Ishbia Family and Oaktree on the same day, but this appears to have been insufficient to offset investor disappointment over the earnings deterioration. For a mortgage lender, profitability is paramount, and a swing to significant losses suggests operational or market headwinds that alarmed equity investors.

BRUNW

Boost Run Inc. Warrant

$5.64−$3.00

-34.7%

BGI

Birks Group IncConsumer Cyclical

$0.35−$0.18

-34.6%

NYSE · Mkt cap $7.4 M

Birks Group announced its intention to voluntarily delist from NYSE American and move to OTCQB trading, triggering a sharp 34.62% sell-off as delisting typically signals financial distress and reduced liquidity for shareholders.

The voluntary delisting announcement is the primary catalyst for the decline. Delisting from a major exchange to over-the-counter markets is widely perceived as a negative signal, associated with reduced regulatory oversight, lower trading liquidity, smaller analyst coverage, and often financial difficulty or failure to meet exchange listing standards. The announcement arrived after market hours on August 6, explaining the same-day ranking as a top loser. A concurrent board director resignation (Imbriglio) on personal grounds is secondary but may amplify concern about corporate governance or internal stability. Voluntary delistings are rarely viewed as neutral events by equity investors, as they restrict accessibility and signal management's acceptance of reduced market standing. The stock's price of $0.35 before the announcement already suggests a distressed equity; the delisting confirms downward trajectory.

UTI

Universal Technical Institute IncConsumer Defensive

$27.86−$14.41

-34.1%

NYSE · Mkt cap $1.2 B

UTI plunged 34% after Q3 earnings on August 6 despite reporting 7.2% revenue growth to $218.9M, driven by management's reduction of full-year guidance citing high school channel shortfall and unfavorable skilled trades mix shift despite strong new student starts.

Universal Technical Institute reported third-quarter results that revealed a classic disconnect between headline revenue growth and underlying business quality. While the 7.2% revenue increase to $218.9M and surge in new student starts sound positive, management simultaneously cut full-year guidance, which triggered the severe selloff. The guidance reduction was attributed to two structural headwinds: weakness in the high school channel (a key enrollment source) and an unfavorable shift in the student mix toward lower-margin skilled trades programs. Investors punished the stock heavily because guidance cuts typically signal management's loss of confidence in near-term execution and margin trajectory, regardless of historical revenue growth. The 34% single-day drop ranks UTI among the day's worst performers, indicating the market viewed the guidance reduction as a material negative surprise rather than a temporary setback.

CVRX

CVRx, Inc.Healthcare

$5.94−$1.91

-33.7%

NASDAQ · Mkt cap $75 M

CVRx reported Q2 2026 earnings on August 6th, likely disappointing the market enough to trigger a 33.69% single-day collapse, making it the seventh-largest loser of the day.

The only substantive news in the provided headlines is CVRx's Q2 2026 earnings release issued on August 6th at 20:05 UTC, which coincides precisely with the stock's massive -33.69% drop the same day. The headline provides no detail on actual results, margins, guidance, or management commentary, so the specific nature of the disappointment cannot be determined from the information provided. However, a one-third single-day decline in a commercial-stage medical device stock following earnings typically reflects either a severe revenue or profitability miss, a negative guidance revision, loss of a major customer, adverse clinical or regulatory developments, or a significant increase in burn rate. The second headline about Pacific Biosciences is unrelated to CVRx and appears to be a data-feed artifact. Without access to the full earnings press release or analyst estimates, the exact catalyst remains unclear, but the timing and magnitude strongly suggest the earnings report itself is responsible.

BIVI

BioVie Inc.Healthcare

$1.36−$0.69

-33.6%

NASDAQ · Mkt cap $10 M

BioVie announced positive Phase 2 results for bezisterim in Parkinson's disease on August 6, but the stock plummeted 33.58%, suggesting the market viewed the data as insufficient or priced in overly bullish expectations beforehand.

BioVie released topline results from its SUNRISE-PD Phase 2 trial showing statistically significant improvements in motor and non-motor symptoms compared to placebo. By conventional biotech standards, positive Phase 2 efficacy data typically supports stock appreciation. However, a severe sell-off following good news usually indicates one of two scenarios: either the market had already priced in these results and expected stronger-than-delivered data, or the headline results masked concerning safety signals, dosing challenges, or commentary suggesting a lengthy or uncertain path to Phase 3. The CEO interview suggests confidence about pivoting to Phase 3, but the market's reaction implies skepticism about either the magnitude of benefit, competitive positioning, or capital requirements ahead. Without access to the full trial data, safety profile, or analyst commentary from the announcement, we cannot pinpoint whether the disappointment stems from efficacy shortfall, risk profile, or valuation reset.

ONT

Onterris, Inc.Industrials

$15.11−$7.57

-33.4%

NYSE · Mkt cap $617 M

Onterris plunged 33% after cutting its 2026 EBITDA guidance on August 6th, reversing the modest market enthusiasm from a surprise earnings beat two days earlier. The guidance cut and deregulation pressure cited by Bank of America overwhelmed the earlier positive EPS surprise.

On August 5th, Onterris reported Q2 earnings that beat EPS estimates by 30.77% but missed revenue expectations with a 20.4% year-over-year sales decline to $186.7 million. The company initially raised EBITDA margin guidance while maintaining cash flow expectations, which initially supported the stock. However, on August 6th the company cut its full-year 2026 EBITDA guidance, a material reversal that triggered the sharp selloff. Bank of America's downgrade cited both the guidance reduction and deregulation pressure facing the environmental services sector as factors darkening the outlook. The 33% single-day drop suggests the market had priced in a recovery scenario that the guidance cut decisively eliminated.

RCON

Recon Technology LtdEnergy

$0.04−$0.02

-33.3%

NASDAQ · Mkt cap $1.7 M

No news headlines are available for the last 48 hours, so the 33% intraday drop cannot be attributed to a specific announced event. The decline is likely driven by sector weakness, technical selling pressure, or undisclosed corporate developments.

RCON is a micro-cap oil services stock trading at $0.04 with negligible liquidity, making it vulnerable to sharp moves on minimal volume. The absence of news in the 48-hour window means the documented catalyst is unknown. Penny stocks in this price range typically experience steep single-day swings due to several factors: broad energy sector selloffs, short-term technical breakdown below key support levels, rumors circulating on retail trading platforms, insider selling, or delayed disclosure of company-specific bad news that may not yet appear in mainstream feeds. Without headline confirmation or structural knowledge of an imminent event, the actual trigger cannot be identified from the available evidence.

CMRC

BigCommerce Holdings, Inc. - Series 1Technology

$2.31−$1.10

-32.3%

NASDAQ · Mkt cap $178 M

Commerce.com reported flat revenue growth, weak forward guidance of $84 million next quarter, and subscription sales declines despite beating earnings estimates, triggering a sharp selloff as investors repriced expectations for stagnant growth.

Commerce.com delivered mixed Q2 2026 results that reveal underlying weakness beneath surface profitability. While the company achieved GAAP profitability and beat operating income guidance, total revenue was flat year-over-year at $84.51 million, missing Wall Street expectations by 0.77 percent. More concerning, subscription sales declined and next quarter's revenue guidance of $84 million suggests no meaningful acceleration. The company also cited margin compression and elevated AI-driven costs. Although ARR grew 2 percent to $360.5 million and operating cash flow remained positive, the combination of stalled top-line growth, declining subscription revenue, reduced full-year guidance, and ongoing cost pressures appears to have shifted investor sentiment from profitability optimism to growth-trajectory disappointment. This type of earnings miss with weakened forward outlook typically triggers sharp repricing in software and SaaS equities.

LegalZoom.com, Inc.Industrials

$5.67−$2.44

-30.1%

NASDAQ · Mkt cap $1.1 B

LegalZoom reported Q2 results that beat earnings estimates and met revenue expectations, but issued disappointing full-year guidance and warned of disruption from Google's AI search shift, triggering the 30% stock collapse.

LegalZoom's second-quarter fundamentals were solid on the surface—revenue of $205.3 million grew 7% year-over-year, subscription revenue grew 11%, and adjusted EBITDA increased 18%, all meeting or exceeding guidance. However, the forward guidance proved deeply concerning. Multiple sources note the company lowered full-year guidance and specifically cited Google's AI search disruption as a material headwind to its business model. For a company that relies heavily on organic customer acquisition through search channels, this acknowledgment signals a structural threat to its go-to-market strategy. The market appears to have interpreted the Q2 beat as masking deteriorating underlying demand trends and validated fears about long-term competitive positioning. The 30% decline reflects investor repricing of future earnings power, not disappointment with past results.

BTMD

Biote CorpHealthcare

$1.59−$0.67

-29.6%

NASDAQ · Mkt cap $46 M

Biote reported Q2 earnings on 2026-08-06 showing a 9.5% revenue decline, break-even results, and a voluntary recall of hormone pellets that disrupted procedure volumes, prompting the 29.6% stock collapse.

Biote released Q2 2026 earnings results early on 2026-08-06 that triggered the sharp sell-off. The company disclosed a voluntary recall of certain hormone pellets supplied by Asteria Health that materially disrupted procedure volumes and contributed to lower revenue. The earnings surprise was negative (-100% earnings surprise according to one headline), and management revised guidance downward while acknowledging supply normalization challenges ahead. The recall, combined with weak top-line performance and the need to wait for supply recovery, appears to have eroded investor confidence in near-term recovery prospects. The stock's position as the 13th biggest loser suggests market-wide disappointment with the company's operational trajectory and ability to execute a turnaround.

EBS

Emergent BioSolutions IncHealthcare

$5.30−$2.22

-29.5%

NYSE · Mkt cap $251 M

Emergent BioSolutions plunged 29.52% after reporting Q2 2026 results showing a massive $180.2 million net loss, worsened by a $191.3 million non-cash impairment charge despite revenue growth of 66%.

The earnings release from August 5 directly precipitated the sell-off. While total revenues improved 66% year-over-year to $234.3 million, the company reported a net loss that deteriorated 1,402% versus the prior year quarter, reaching $180.2 million. The headline explicitly attributes much of this loss to a $191.3 million non-cash impairment charge, suggesting significant asset write-downs. This combination of deteriorating bottom-line performance despite top-line growth typically signals either operational challenges, unexpected charges related to acquisitions or product lines, or a reassessment of asset values that destroys shareholder confidence. The magnitude of the impairment relative to quarterly revenue indicates a material structural problem rather than a temporary operational issue.

TTD

Trade Desk Inc-TheCommunication Services

$17.67−$5.57

-29.3%

NASDAQ · Mkt cap $6.7 B

The Trade Desk crashed 29.35% after reporting Q2 revenue of $715 million, significantly missing the $752.61 million consensus estimate, while also issuing weak forward guidance of $650 million for Q3.

The Trade Desk's earnings report on August 6, 2026, triggered the sharp selloff. While the company beat adjusted EPS expectations at $0.34 versus $0.18 estimated, the revenue miss of approximately $37.6 million below consensus and the notably weak Q3 guidance of $650 million dominated investor sentiment. The guidance figure is particularly concerning as it represents a sequential decline from Q2's $715 million, suggesting either seasonal weakness or deterioration in advertising demand. Revenue growth of only 3% year-over-year also indicates deceleration in the programmatic advertising platform's expansion. The ad-tech sector was experiencing significant volatility on the day, with traders actively differentiating between winners and losers based on earnings results, making TTD's miss especially punishing in this sorting environment.

INSG

Inseego CorpTechnology

$5.30−$2.14

-28.8%

NASDAQ · Mkt cap $70 M

Inseego beat Q2 revenue expectations but slashed full-year 2026 guidance to $155 million due to engineering bottlenecks and slower Fixed Wireless Access recovery, triggering a 28.76% stock collapse as investors repriced forward earnings.

The earnings headlines establish that Inseego delivered a genuine revenue surprise in Q2 2026, posting $44 million in top-line results and beating guidance with 28% sequential growth. However, the company simultaneously lowered its full-year 2026 revenue guidance to $155 million, citing specific operational headwinds: engineering bottlenecks constraining production and a slower-than-expected recovery in its Fixed Wireless Access (FWA) segment. The company also reported a net loss of $8.4 million against only $0.5 million in adjusted EBITDA, signaling profitability remains elusive despite revenue growth. For a smaller-cap wireless infrastructure play, a major guidance cut typically overwhelms a single-quarter beat because it signals deteriorating visibility and prolonged margin pressure. Investors appear to have punished the stock heavily on the forward outlook revision rather than the backward-looking Q2 performance.

OLOX

Olenox Industries Inc.Industrials

$3.34−$1.30

-27.7%

NASDAQ · Mkt cap $3.7 M

Olenox announced regaining Nasdaq compliance on filing requirements on August 6, but this positive news contradicts the stock's 27.67% plunge, suggesting the market had already priced in compliance recovery or is reacting to unrelated negative sentiment or technical selling.

The sole headline provided reports that Olenox regained compliance with Nasdaq periodic filing requirements and received confirmation from the exchange on August 6. This is ostensibly positive news, as it resolves a regulatory overhang. However, the stock fell nearly 28% on the same day the announcement was made, which is counterintuitive. This disconnect suggests either the market had already anticipated compliance reinstatement and the announcement failed to meet higher expectations, or the headline is incomplete and obscures a broader negative context such as poor earnings, operational challenges, or guidance cuts buried within the full press release. Alternatively, the plunge may reflect technical selling, short covering unwinding, or market indifference to compliance news given other fundamental concerns not visible in the truncated headline. Without the full text of the announcement or concurrent earnings data, the precise trigger remains unclear.

ELPW

Elong Power Holding Limited Class A Ordinary SharesIndustrials

$0.11−$0.04

-27.4%

NASDAQ · Mkt cap $2.2 M

Elong Power announced a 1-for-45 share consolidation, which typically signals financial distress and dilution concerns; the stock fell 27.36% following the announcement and related corrections on the effective date.

The headlines establish that Elong Power announced and then corrected the effective date of a 1-for-45 share consolidation on August 6, 2026. Share consolidations are typically undertaken by companies facing regulatory delisting risk or seeking to stabilize a stock trading at penny stock levels. The company also closed a US$1.38 million public offering on August 4, suggesting capital needs. While consolidations mechanically preserve the same market cap (each share worth 45x more post-split), they often trigger negative sentiment because they are associated with financial weakness. Investors frequently interpret such moves as admission of structural problems or precursors to further dilution. The timing of the consolidation announcement coinciding with the 27.36% drop suggests the market is repricing risk around the company's fundamentals and capital structure, not merely the mechanics of the consolidation itself.

ATS

ATS Corporation Common SharesIndustrials

$20.51−$7.53

-26.8%

NYSE · Mkt cap $1.9 B

ATS fell 26.85% after reporting Q1 earnings and revenues that missed analyst estimates by 10.71% and 3.66% respectively, combined with the announcement of a Fixed Cost Transformation Program signaling operational challenges.

ATS released first quarter fiscal 2027 results on August 6, 2026, that disappointed on both the top and bottom lines. Earnings came in 10.71% below expectations and revenue missed by 3.66%, indicating weaker-than-anticipated business performance. The company simultaneously announced a Fixed Cost Transformation Program, which typically signals management recognition of profitability pressure and the need to restructure operations. While the shareholder meeting approved the board and auditor reappointment, and the chair outlined plans for margin improvement, M&A activity, and growth, the immediate catalyst for the sharp decline appears to be the earnings miss and transformation announcement. The market often interprets cost-cutting programs as acknowledgment that organic growth and current margins are insufficient, triggering sell-offs in growth or quality-oriented stocks.

CNTX

Context Therapeutics Inc.Healthcare

$0.51−$0.18

-26.1%

NASDAQ · Mkt cap $45 M

Context Therapeutics reported Q2 2026 results on August 5th showing $43M cash through Q4 2027, but the market appears to have reacted negatively to the lack of near-term clinical catalysts, with key readouts delayed to Q2 2027.

The company's earnings release explicitly states that initial clinical readouts for its two prioritized programs (CTIM-76 and CT-202) are expected beginning in Q2 2027, which is approximately nine months away. For a clinical-stage biotech with a market cap around $40M based on current pricing, the absence of near-term clinical data or significant pipeline progress likely disappointed investors. The cash guidance through Q4 2027 indicates the company is runway-constrained and dependent on those 2027 readouts for validation. Biotech stocks frequently decline sharply on earnings when investors perceive extended timelines without intermediate catalysts or when cash runway proves shorter than hoped. The -26% drop is consistent with a reassessment of near-term value drivers and potential concerns about funding needs before clinical inflection points arrive.

QDEL

Quidel CorpHealthcare

$16.35−$4.48

-25.6%

NASDAQ · Mkt cap $955 M

QuidelOrtho reported Q2 revenue that beat expectations with 2.8% year-over-year growth, but the stock plummeted 25.58% on disappointing full-year revenue guidance, signaling management's outlook has deteriorated despite the quarterly beat.

The headlines establish that QuidelOrtho delivered better-than-expected Q2 2026 sales of $630.9 million, which ordinarily would be considered positive. However, the first headline explicitly states the stock dropped 21.6% following the earnings announcement, and the article references the company's full-year revenue guidance as a key negative factor. While the headline does not provide the specific guidance figure or prior expectations, the directional signal is clear: management's forward outlook disappointed investors enough to override the quarterly revenue beat. This is a classic earnings-driven sell-off driven by guidance revision rather than current quarter performance. The earlier options volatility surge on August 5th suggests the market anticipated a significant move, likely from traders positioning ahead of the earnings release.

TRIP

TripAdvisor IncConsumer Cyclical

$10.41−$3.56

-25.5%

NASDAQ · Mkt cap $1.1 B

TripAdvisor reported Q2 2026 earnings that missed both revenue and profit estimates by double-digit percentages, triggering a sharp 25% sell-off as investors repriced the stock on weaker-than-expected operational performance.

TripAdvisor released second quarter 2026 earnings on August 6, 2026 that fell materially short of Wall Street expectations. The company reported a revenue miss of 13.12% and an earnings miss of 16.67% versus consensus estimates. Multiple news outlets published analysis of the shortfall within hours of the earnings release, with headlines noting lower sales and earnings compared to the prior year quarter. The magnitude of the misses and the stock's 25% single-day decline suggest the market viewed the results as a significant disappointment that warranted substantial downward valuation adjustment. No forward guidance revision or commentary is explicitly mentioned in the headlines, so whether management cut outlook or merely reported a weak quarter is not entirely clear from the evidence provided.

AKBA

Akebia Therapeutics IncHealthcare

$0.95−$0.33

-25.4%

NASDAQ · Mkt cap $236 M

Akebia reported Q2 earnings on August 5-6 that beat earnings expectations but missed revenue targets, with Vafseo growth offset by Erixia declines and planned 2027 price cuts signaling margin pressure ahead.

The earnings headlines present a mixed picture. Vafseo revenue grew to $21.3 million with over 10,500 patients on therapy, and the company beat earnings per share estimates by 33.33%, suggesting cost discipline. However, total revenue came in 5.80% below consensus, indicating the Vafseo gain was outpaced by declines elsewhere, likely Erixia. More importantly, management's guidance of strategic price adjustments for 2027 signals anticipated reimbursement or competitive pressure that will constrain future margins. For a small-cap biotech trading near $1, a revenue miss combined with forward guidance suggesting price headwinds is typically punished hard, as investors price in slower growth and profitability challenges. The 25% single-day drop reflects repricing of growth and cash-burn trajectory.

SEZL

Sezzle Inc. - Common StockFinancial Services

$178.94−$43.65

-25.1%

NASDAQ · Mkt cap $3.8 B

Sezzle delivered strong Q2 earnings beating revenue expectations and showing 51.7% year-over-year growth, yet the stock fell 25% anyway, a classic "sell the news" reaction likely driven by investor disappointment over forward guidance or margin concerns despite the beat.

Sezzle reported better-than-expected results on August 6: Q2 revenue of $149.7 million beat consensus, up 51.7% year-over-year, with gross margin of 11.3% above expectations and active subscribers up 76.4% to 854,000. Despite these headline beats, the stock dropped sharply. This is consistent with a "sell the news" pattern where strong results fail to meet elevated market expectations. One pre-earnings report noted the stock had rallied 106% in three months heading into earnings and flagged "elevated valuation and margin pressures" as key risks. The disconnect suggests investors may have been concerned about forward guidance, growth deceleration signals, or continued profitability challenges in the buy-now-pay-later sector, all of which can trigger sharp reversals even after a beat.

YYAI

Connexa Sports Technologies Inc.Technology

$0.08−$0.03

-24.3%

NASDAQ · Mkt cap $3.9 M

No news headlines were reported in the last 48 hours for YYAI, so the 24% drop cannot be attributed to a specific announced event. The decline likely reflects either technical selling pressure, delayed market reaction to prior news, or broader sector weakness.

The absence of recent headlines makes it impossible to pinpoint a concrete cause for YYAI's steep 24% single-day loss. Given the stock's very low price of $0.08, it may be susceptible to technical factors such as stop-loss cascades, short covering reversals, or algorithmic liquidations that can trigger sharp moves independent of company-specific news. Alternatively, the decline could reflect a delayed market reaction to earnings, a business update, or sector news released more than 48 hours ago that has only now gained traction. For micro-cap or penny stocks like this, intraday volatility is often disconnected from news cycles. Without headline evidence or structural information about the company's capital structure or investor composition, the root cause remains speculative.

HONA

Honeywell Aerospace Inc.Industrials

$156.81−$47.30

-23.2%

NASDAQ · Mkt cap $51 B

Honeywell Aerospace plunged 23% after cutting its 2026 full-year sales and earnings guidance on August 6, citing ongoing supply-chain constraints that limited production and forced a shift toward lower-margin sales during what was its first standalone quarter since spinning off from Honeywell Int…

The headlines establish that Honeywell Aerospace reported second-quarter results and immediately reduced its 2026 outlook on August 5–6, 2026. The company reported only 5% organic sales growth and explicitly blamed supply-chain bottlenecks for constraining production and forcing unfavorable product mix shifts toward lower-margin offerings. This guidance cut is particularly material because it represents the company's inaugural quarter as a standalone entity following its spin-off from Honeywell International, making first impressions critical to investor confidence. The sell-off is also contextually notable because peers in the aerospace sector are raising outlooks, which makes Honeywell Aerospace's downgrade stand out as a relative disappointment. Secondary market headwinds (rising oil prices and Treasury yields) contributed to a weaker equity market overall on August 6, but those do not account for a 23% single-day loss; the company-specific guidance reduction is the primary driver.

RITR

Reitar Logtech Holdings Limited Ordinary sharesIndustrials

$0.19−$0.06

-22.8%

NASDAQ · Mkt cap $4.8 M

No headlines were found in the last 48 hours to explain the 22.82% drop in RITR. The move is likely driven by sector pressure, technical selling, or an unannounced event not yet reflected in financial news feeds.

The absence of recent headlines makes it impossible to pinpoint a specific catalyst for RITR's sharp decline. Reitar Logtech is a small-cap logistics technology company, and stocks in this category can be sensitive to several types of pressures: broad market weakness in the technology or transportation sectors, profit-taking after a prior run-up, liquidity-driven selling due to low average trading volume typical of penny stocks, or delayed disclosure of negative information not yet aggregated by Yahoo Finance. Without news confirmation, any explanation is speculative. The stock's low price point ($0.19) suggests it may be illiquid and prone to volatile swings on modest volume shifts. A company-specific announcement, earnings miss, or negative analyst downgrade could explain the move but is not visible in the provided data.

ADV

Advantage Solutions IncCommunication Services

$25.46−$7.35

-22.4%

NASDAQ · Mkt cap $454 M

ADV dropped 22.41% despite beating revenue expectations and reiterating full-year guidance, driven by a 12% decline in adjusted EBITDA and a massive earnings miss as weakness in Branded Services and execution challenges offset growth in other segments.

Advantage Solutions reported Q2 2026 revenue of $757 million, up 3% year-over-year and beating estimates by 3.03%, which alone would normally support the stock. However, the company posted a net loss with an earnings surprise of -317.88%, and adjusted EBITDA fell 12% to $76 million despite revenue growth. The headline explicitly states profitability remains under pressure due to weakness in Branded Services and execution challenges in Retailer Services. Though management reiterated full-year guidance and highlighted AI-driven efficiency gains and strong experiential demand, investors appear to have penalized the stock heavily for the profitability deterioration and the miss on the bottom line, which signals operational headwinds that guidance alone did not assuage.

MGRX

Mangoceuticals, Inc. - Common StockHealthcare

$0.52−$0.14

-21.9%

NASDAQ · Mkt cap $7.2 M

MGRX fell 21.9% likely due to investor disappointment that the Nuclea Energy partnership announcement on August 5 did not include concrete funding, regulatory approval, or a clear path to commercialization of the Morpheus microreactor, combined with ongoing compliance risk signaled by the August …

On August 4, Mangoceuticals disclosed it received a 180-day extension to regain compliance with Nasdaq's minimum bid price requirement, a red flag for financial stability. The following day, the company announced that its merger partner Nuclea Energy had executed a Memorandum of Understanding with Utah's Office of Energy Development regarding a nuclear test reactor site. While framed as progress, an MOU is a non-binding exploratory agreement and does not guarantee funding, regulatory clearance, or project advancement. The stock's sharp decline suggests the market viewed this as insufficient news to justify the company's valuation or reverse its compliance troubles. For a micro-cap with price-compliance issues, investors likely needed either concrete capital injection news, a regulatory milestone, or clear merger closing date rather than an early-stage partnership agreement.

MTNE.WT

CH4 Natural Solutions Corp WT

$0.25−$0.07

-21.9%

SNES

Senestech IncBasic Materials

$1.29−$0.36

-21.8%

NASDAQ · Mkt cap $6.7 M

SenesTech reported record Q2 revenue and strong e-commerce growth on August 5–6, yet the stock fell 21.82%, suggesting the market's positive reaction to earnings may have reversed due to unmet profit expectations, weak gross margin detail, or disappointment with B2B pipeline confidence.

The headlines establish that SenesTech announced record Q2 2026 revenue of $770,000 with a 186% surge in e-commerce sales and introduced new assessment services for B2B customers. On the surface, these are positive operational developments. However, a sharp 21.82% drop immediately following earnings typically indicates that investor expectations were higher, or that the margin/profitability outlook fell short. The headlines do not provide net income, EPS, guidance, or details on gross margin sustainability, making it difficult to pinpoint whether the disappointment stems from valuation concerns, slowing path to profitability, or guidance being lower than anticipated. For a micro-cap stock like SNES trading near $1.29, a single quarter of positive topline growth is often insufficient if it does not signal a clear route to profitability or meaningful margin expansion. The drop likely reflects a "sell the news" reaction rather than rejection of the business fundamentals themselves.

NXTT

Next Technology Holding Inc.Technology

$0.07−$0.02

-21.6%

NASDAQ · Mkt cap $9.8 M

No news headlines were found in the last 48 hours, so the 21.57% drop cannot be attributed to a specific disclosed catalyst. The decline likely stems from technical selling, liquidity constraints, or undisclosed company developments in a micro-cap stock.

NXTT is trading at $0.07, a price level typical of highly speculative micro-cap stocks with thin liquidity and high volatility. The absence of any news coverage in the 48 hours preceding a major one-day drop suggests the catalyst was either not material enough for press pickup, occurred via social media or private channels, involved a technical breakdown in a thinly traded security, or relates to broader micro-cap sector weakness not captured in individual headlines. Stocks at this price point are often subject to sudden reversals on modest volume shifts, short-seller activity, or margin calls. Without access to institutional ownership data, insider trading records, or real-time order flow, we cannot determine whether this was an event-driven move or pure technical/sentiment-driven selling.

FCUV

Focus Universal, Inc.Technology

$8.08−$2.14

-21.1%

NASDAQ · Mkt cap $5.7 M

FCUV fell 21% despite announcing it will showcase AI technology at an investor conference, suggesting the market reacted to broader factors unrelated to the positive headline or sold on the news after a prior run-up.

The sole headline on record is a corporate event announcement that is typically positive or neutral—Focus Universal will present its deterministic AI technology at the H.C. Wainwright conference on August 6, the same day as the sharp drop. This type of visibility event rarely triggers a 21% sell-off on its own. The decline is likely driven by one or more of the following: (a) a significant negative announcement or guidance cut released outside the provided news window, (b) a sell-the-news reaction if the stock rallied sharply before the conference announcement, (c) broader sector weakness in IoT or AI-related stocks, or (d) technical/momentum factors. Without access to earnings, insider trading activity, competitor news, or market-wide data from August 6, the specific catalyst remains unclear.

CLFD

Clearfield IncTechnology

$26.74−$7.04

-20.8%

NASDAQ · Mkt cap $379 M

Clearfield beat Q3 earnings and won a landmark $22 million data center order, but the stock fell 20.84% likely due to reduced full-year guidance and slowdowns in the broadband market offsetting the positive headline wins.

The headlines present a mixed earnings picture. On the positive side, Clearfield delivered a 10% earnings surprise, 13% year-over-year revenue growth to $43.9 million, a 28% sequential jump, and secured a significant $22 million hyperscale data center contract. However, the first headline explicitly states the company is "navigating broadband market slowdowns and reduced full-year guidance." In equity markets, forward guidance cuts typically trigger sharp selloffs regardless of current quarter performance, especially when they signal structural headwinds in a core business segment. The revenue miss of 0.31% relative to estimates and the guidance reduction appear to have dominated investor sentiment, overwhelming the positive data center win announcement.

MGN

Megan Holdings LimitedIndustrials

$0.11−$0.03

-20.4%

NASDAQ · Mkt cap $3.7 M

MGN fell 20.45% with no news headlines in the last 48 hours, making the specific catalyst unclear; the drop may reflect technical selling, delayed news dissemination, or broader market factors affecting microcap stocks.

No news headlines were reported for MGN in the last 48 hours, so the cause of the 20.45% decline cannot be grounded in a specific announced event. For a microcap stock trading at $0.11 on NASDAQ, price swings of this magnitude are common and can be driven by several categories of factors: thin liquidity and retail trading activity, technical support breaks or momentum reversals, delayed regulatory filings or insider announcements not yet picked up by major news feeds, sector-wide weakness in the underlying business category, or simply low-volume panic selling. Without headlines or access to company fundamentals, intraday trading patterns, or recent SEC filings, it is not possible to identify which of these mechanisms drove today's move.

OMH

Ohmyhome Limited - Ordinary SharesReal Estate

$0.09−$0.02

-20.2%

NASDAQ · Mkt cap $7.7 M

No news headlines were found in the last 48 hours, so the 20% drop cannot be directly attributed to a disclosed event. The decline likely reflects technical selling, broader market conditions, or undisclosed company developments.

The absence of recent news headlines means we cannot point to a specific catalyst such as earnings, guidance, regulatory action, or corporate announcements. OMH is a small-cap micro stock trading at $0.09, which typically exhibits higher volatility and may be more susceptible to technical factors, retail trading activity, or sentiment shifts than large-cap securities. At this price level, stocks often experience sharp single-day moves driven by momentum, short covering reversals, or sector-wide pressure rather than fundamental news. Without headlines to anchor the analysis, the decline could reflect delayed reactions to earlier news, rumors on social media or retail trading platforms, or simple profit-taking after prior gains.

AGL

agilon health, inc.Healthcare

$86.56−$21.20

-19.7%

NYSE · Mkt cap $1.5 B

Agilon Health crashed 19.67% despite beating Q2 earnings and revenue estimates with strong guidance, suggesting the market's reaction reflects forward guidance concerns, valuation repricing, or execution risk rather than operational miss.

The headline evidence presents a paradox: all five news items from the past 48 hours describe positive Q2 2026 results for Agilon Health, including beats on both earnings and revenue, upbeat full-year sales guidance, exceeded medical margin guidance, and strong adjusted EBITDA. The earnings surprise magnitude (1,633% on EPS) and revenue beat (3.33%) were substantial. Yet the stock fell nearly 20%, ranking it the 37th biggest loser. This disconnect suggests the market either (1) interpreted forward guidance as insufficient relative to valuation expectations despite the optimistic language, (2) identified operational or margin risk in the detailed metrics not captured in headlines, (3) experienced a post-earnings sell-the-news reaction typical of healthcare stocks after big moves, or (4) reacted to commentary on cost pressures or competitive dynamics mentioned in the earnings call but not emphasized in these particular headlines. Without access to the full earnings transcript, guidance specifics, or analyst reactions, we cannot pinpoint whether the sell-off targets a specific line item or reflects broader valuation reset.

APP

AppLovin CorporationCommunication Services

$335.70−$82.11

-19.7%

NASDAQ · Mkt cap $103 B

AppLovin reported weaker-than-expected Q2 revenue and issued disappointing guidance, triggering a sharp selloff in the ad-tech sector as investors reassess winners versus losers in the space.

AppLovin shares plummeted 19.65% after the company reported revenue that fell short of expectations and provided guidance that disappointed the market. Multiple headlines confirm this earnings miss narrative, with one explicitly stating the firm's sales and outlook disappointed, while another notes AppLovin crashed 20% as traders separated ad-tech winners from losers during earnings season. The context of rising AI spending costs appears to be pressuring margins or visibility. Notably, competitor Magnite jumped 18% and Trade Desk slid 6%, suggesting sector-wide volatility but differentiated outcomes based on execution. The Pixalate report mentioning AppLovin rankings suggests the broader ad-tech landscape is under scrutiny. This is a classic earnings-driven rout where guidance revision or top-line miss combined with operational headwinds triggers immediate repricing.

PRTH

Priority Technology Holdings IncTechnology

$5.35−$1.30

-19.5%

NASDAQ · Mkt cap $464 M

Priority Technology beat both earnings and revenue estimates on August 6, yet the stock plunged 19.49% the same day, suggesting the market reacted negatively to forward guidance, margin concerns, or debt levels despite the earnings surprise.

The earnings headlines report that PRTH delivered a +3.57% earnings beat and +1.26% revenue beat for Q2 2026, which normally would support a stock price rise or at minimum stability. However, the stock fell sharply on the announcement day, indicating the market focused on elements beyond the headline numbers. A pre-earnings analysis note flagged debt concerns, margin pressure, and uneven demand as headwinds, suggesting investors may have reacted to commentary about profitability trends, future guidance reductions, or balance sheet concerns revealed in the full earnings release. The earnings surprise alone does not explain the 19% drop; the negative reaction likely stems from forward-looking statements or operational metrics disclosed in the full earnings call that contradicted the near-term growth narrative.

TGE.WT

The Generation Essentials Group

$0.15−$0.03

-19.4%

NYSE

No news headlines were found in the last 48 hours, so the 19.39% drop cannot be directly attributed to a specific announcement or event; the decline is likely driven by broader market conditions, technical selling, or undisclosed company-specific news not yet indexed.

The absence of recent news headlines leaves no concrete explanation for today's sharp 19.39% decline in The Generation Essentials Group. A stock trading at $0.15 with a warrant structure (indicated by the .WT ticker suffix) is typically highly illiquid and volatile, meaning even modest volume shifts or sector rotations can produce outsized percentage moves. Possible drivers include: first, a delayed earnings miss or guidance cut that has not yet surfaced in major news feeds; second, sector-wide weakness in consumer or retail stocks; or third, technical capitulation or stop-loss selling among retail holders. Warrants are particularly sensitive to shifts in underlying volatility and time decay, so deterioration in the parent company's prospects or equity price could have magnified the loss here even without explicit news coverage.

HUBS

HubSpot IncTechnology

$202.38−$47.82

-19.1%

NYSE · Mkt cap $12 B

HubSpot reported a Q2 earnings beat but issued full-year revenue guidance below analyst expectations and signaled longer sales cycles and budget pressure, triggering a 19% sell-off as Wall Street shifted to a cautious stance on near-term growth.

HubSpot delivered revenue growth of 20% and beat Q2 estimates, which ordinarily would support a stock price. However, the headlines consistently emphasize that management's full-year revenue guidance came in below analyst forecasts, and the earnings call revealed headwinds: longer sales cycles, customer budget scrutiny, and a need to lower entry prices and widen AI trials to drive adoption. This guidance miss and forward-looking pressure overshadowed the quarterly beat. Multiple sources confirm analyst downgrades and price target cuts followed immediately. The broader software sector also declined on the day, suggesting some sector-wide concern over AI pricing power and demand dynamics, but HubSpot's specific guidance cut appears to be the primary trigger for its outsized 19% decline and position as the 41st biggest loser on the day.

DDOG

Datadog IncTechnology

$229.32−$53.95

-19.0%

NASDAQ · Mkt cap $83 B

Datadog reported a revenue beat and raised full-year guidance, but the stock fell 19% because investors expected faster growth acceleration and were disappointed by decelerating bookings and softer-than-hoped forward guidance, triggering a sell-the-news reaction in a tough software earnings envir…

Datadog delivered objectively strong Q2 results: revenue of $1.12 billion beat expectations and grew 36% year-over-year, with earnings above estimates and a full-year outlook raise. However, the market's reaction hinged on forward momentum indicators. Multiple headlines emphasize that September quarter and full-year guidance underwhelmed relative to expectations, bookings growth decelerated, and investors had built unrealistic expectations after the stock had more than doubled earlier in 2026. The sell-off also occurred amid a sector-wide pain trade affecting software stocks regardless of earnings quality. This is a classic case of execution mismatch with elevated expectations rather than operational failure.

BROS

Dutch Bros Inc.Consumer Cyclical

$53.32−$12.43

-18.9%

NYSE · Mkt cap $8.1 B

Dutch Bros beat Q2 earnings and raised full-year guidance but disappointed investors with modest same-store sales growth (5.8%) and weak Q3 outlook (4-5%), triggering an 18.9% sell-off despite the headline earnings beat.

The earnings call on August 6 reveals a classic "beat but guide lower" scenario. While Dutch Bros topped Q2 estimates with 32% revenue growth and raised full-year guidance, the market fixated on two negatives: same-store sales growth of 5.8% fell short of buy-side expectations, and Q3 guidance of 4-5% signaled further deceleration. The $105 million Salad and Go acquisition announcement, while strategic for unit growth toward 2,029 locations by 2029, may have also raised concerns about capital allocation and integration risk during a slowdown period. Investors likely interpreted the guidance as a signal that the company's momentum is cooling despite headline operational gains, explaining the sharp intraday reversal from initial modest losses to nearly 19% down.

FOUR

Shift4 Payments IncTechnology

$43.36−$9.99

-18.7%

COLL

Collegium Pharmaceutical IncHealthcare

$29.13−$6.63

-18.5%

NASDAQ · Mkt cap $729 M

Collegium beat Q2 earnings and revenue estimates with 6% YoY growth and a completed ADHD acquisition, yet the stock fell 18.5%, suggesting the market expected substantially stronger guidance or margin performance than delivered.

The headline evidence presents a puzzle: Collegium reported a 14.29% earnings surprise and 1.20% revenue beat for Q2 2026, with net revenues of $199.9 million up 6% YoY, strong ADHD portfolio growth, and completion of the AZSTARYS acquisition. By traditional metrics, this is a positive earnings report. However, one headline explicitly states the company "fell short of the market's revenue expectations," and another notes the stock "drops" after reporting "sales below analyst estimates." This contradiction suggests the initial estimates may have been revised downward between release and wire reports, or full-year guidance fell materially short of prior expectations. The 18.5% decline is severe enough to indicate either a disappointing forward outlook, a material margin contraction not highlighted in the snippets, or a significant shift in market perception of the pain portfolio weakness offsetting ADHD gains. Without full guidance language or detailed margin commentary, the exact trigger cannot be pinpointed, but forward earnings power appears to be the primary concern.

GOGO

Gogo IncCommunication Services

$3.64−$0.83

-18.5%

NASDAQ · Mkt cap $360 M

Gogo dropped 18.5% after reporting Q2 earnings that missed analyst estimates on both revenue and earnings, with revenue declining sequentially and year-over-year despite some bright spots in military/government services.

Gogo announced Q2 2026 earnings on August 6 with revenue of $222.8 million, down 1% year-over-year and 2% from Q1, missing consensus estimates by 2.34%. More critically, earnings missed by 66.67%, with a net loss of $2.0 million reported. While the company noted positive growth in military and government connectivity revenue, up 40% versus prior year, this was insufficient to offset broader weakness. Analysts subsequently cut the fair value estimate from $10.50 to $9.50, a 9.5% reduction citing churn risk alongside optimism about spectrum assets. The sequential revenue decline combined with the magnitude of the earnings miss appears to have triggered institutional and retail selling, pushing the stock into the day's top losers.

CELH

Celsius Holdings IncConsumer Defensive

$23.77−$5.39

-18.5%

NASDAQ · Mkt cap $8.0 B

Celsius Holdings reported Q2 revenue of $818 million, missing Wall Street consensus estimates of $870 million by 7.4%, with core Celsius brand sales down 12% and non-GAAP earnings also missing guidance, triggering the 18% single-day selloff.

The stock decline is directly attributable to Celsius's second-quarter earnings miss released on August 6, 2026. Revenue came in at $818 million versus expected $870 million, marking the company's first revenue miss in five quarters and signaling a loss of investor confidence in the recovery narrative. More concerning was the 12% decline in core Celsius brand sales, which represents the company's flagship product line. While growth at Alani Nu (up 56%) and the completed Rockstar integration provided some offset, these gains were insufficient to meet expectations. Non-GAAP earnings per share of $0.36 fell 13.9% below analyst consensus. The magnitude of the miss and break in the five-quarter streak of beats appear to have shaken confidence in management's guidance and execution, prompting the substantial institutional and retail sell-off that followed the earnings call.

ONFO

Onfolio Holdings Inc. Common StCommunication Services

$0.06−$0.01

-18.3%

NASDAQ · Mkt cap $334 K

Onfolio announced a 1-for-50 reverse stock split to regain Nasdaq compliance, a move typically viewed negatively by markets as it signals financial distress and dilution risk despite the lower share count.

Onfolio announced a 1-for-50 reverse stock split effective today to restore compliance with Nasdaq's minimum bid price requirement. The company will reduce outstanding shares to approximately 850,000 shares. Reverse stock splits are generally perceived as negative signals because they are often associated with companies in financial distress struggling to meet exchange listing standards. While the announcement was made this morning, the stock declined 18.34% during the day, suggesting investors sold on the news or had already anticipated the split and reacted negatively. The split itself does not create economic value; it merely consolidates shares. Markets often interpret such actions as admission of fundamental weakness, particularly when a company has repeatedly fallen below price compliance thresholds. This structural signal, combined with potential pre-announcement positioning, likely explains the day's decline.

SXTC

China SXT Pharmaceuticals IncHealthcare

$0.05−$0.01

-18.2%

NASDAQ · Mkt cap $2.4 M

China SXT Pharmaceuticals announced a share consolidation on August 5, which likely triggered the 18% drop as investors reacted to the dilutive restructuring.

The company announced a share consolidation of its Class A ordinary shares on August 5, 2026. While the headline does not provide full details of the consolidation ratio or terms, share consolidations in distressed or low-priced stocks are typically viewed negatively by the market because they often signal financial stress, reverse the psychological damage of a collapsing stock price without improving fundamentals, and may indicate preparation for delisting avoidance or restructuring. The timing between the announcement on August 5 and the observed 18% drop on August 6 is consistent with market reaction to the news. However, the truncated headline does not specify the exact consolidation ratio, reverse split terms, or any accompanying statements about the company's rationale, so some specifics remain unclear. The drop magnitude suggests investor concern about the structure or implications of the consolidation itself.

VISN

Vistance Networks, Inc.Technology

$10.11−$2.22

-18.0%

NASDAQ · Mkt cap $1.5 B

Vistance Networks fell 18% on the day it reported Q2 2026 earnings and announced a special board-approved distribution, likely due to disappointing results or guidance that overshadowed the positive cash return news.

Vistance announced two material corporate events on the same day: second-quarter financial results and board approval of a special distribution to shareholders. The 18% decline suggests the earnings report contained negative surprises, such as missed revenue or profit targets, weakened forward guidance, or margin compression in the intelligent network solutions business. While special distributions typically appeal to income-focused investors, they often signal the company believes cash is in excess of near-term deployment needs or growth opportunities, which can be read as a lack of conviction in future growth prospects. The timing of both announcements simultaneously makes it difficult to isolate which drove the selling, but the magnitude of the decline points more toward earnings disappointment than enthusiasm dampening over the capital return.